A new U.S.-based patient registry is enrolling people with myasthenia gravis (MG) to help researchers better understand how the disease progresses, how treatments are used in the real world, and how MG affects patients’ daily lives. Launched by Alira Health in partnership with the Autoimmune Neurology Alliance, the…
News
Myasthenia gravis (MG) patients who lack the three most common disease-causing antibodies often respond poorly to standard immunosuppressive medications, with many — especially those with hard-to-treat disease — failing to see their symptoms fully controlled. That’s according to a single-center study in Greece that also showed that only about…
Physical activity and respiratory (breathing) muscle training may help people with myasthenia gravis (MG) reduce symptoms and improve daily functioning, especially when programs are adapted to their needs, according to a review study. “Individualized exercise programs are essential to ensure safety and optimize adherence,” the researchers wrote.
Zilbrysq (zilucoplan) helped ease disease symptoms and improve quality of life for most people with generalized myasthenia gravis (gMG) in an expanded access program (EAP) in France, a study showed. EAPs provide access to experimental therapies, or those already approved but not yet on the market, outside clinical…
Vyvgart (efgartigimod alfa-fcab) may be a safe and effective treatment for children and adolescents with juvenile myasthenia gravis (JMG), according to new real-world data from China. The study found that the therapy, developed by Argenx and currently approved for certain adults with…
Most children with juvenile myasthenia gravis (JMG) develop mild disease marked by eye muscle weakness, with more severe symptoms seen in those who are older when they start showing signs of disease, according to a single-center study in China. Data also suggested that blood levels of self-reactive antibodies against anti-acetylcholine…
People with myasthenia gravis (MG) are twice as likely to be diagnosed with other autoimmune diseases, both before and after an MG diagnosis, than a matched general population, a new study involving patients from Denmark found. This predisposition was particularly strong among patients younger than 50 — meaning those…
Enrollment is ongoing in a global, late-stage clinical trial testing the safety and efficacy of telitacicept in adults with generalized myasthenia gravis (gMG), with top-line data expected in the first half of next year, Vor Bio said. The Phase 3 UPSTREAM MG study (NCT06456580), previously known…
A late-stage clinical trial testing KYV-101, a CAR T-cell therapy for adults with hard-to-treat generalized myasthenia gravis (gMG), is still enrolling gMG patients to take part in its Phase 3 portion. This portion of the Phase 2/3 KYSA-6 trial (NCT06193889) is open to people with gMG, ages…
Treatment with Vyvgart (efgartigimod alfa) may safely and effectively treat acute exacerbations and symptom worsening in people with generalized myasthenia gravis (gMG), a real-world study in China shows. The treatment demonstrated a rapid onset of action, with significant improvements seen after the first dose, as well as a…
Recent Posts
- The burden of chronic illness life when others don’t believe you
- Regaining control over life when MG weighs me down
- New US patient registry to track MG using real-world data
- Standard treatments don’t always work for triple-seronegative MG
- Exercise, breathing training may help ease myasthenia gravis symptoms